Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial
Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial
复制标题
治疗前体重指数作为局部晚期鼻咽癌放化疗患者的独立预后因素：随机试验的结果
DOI：
10.1016/j.ejca.2013.01.027
复制
发表时间：
2013-05-01
影响因子：
8.4
通讯作者：
Hong, Ming-Huang
中科院分区：
文献类型：
--
作者：
Huang, Pei-Yu;Wang, Cheng-Tao;Hong, Ming-Huang
目的：探讨局部晚期鼻咽癌患者放化疗前体重指数（BMI）与临床疗效的关系。方法：2002年8月至2005年4月，招募了400例III期或IVa期鼻咽癌患者，进行诱导化疗联合放疗或同时放疗的随机临床试验。放化疗根据世界卫生组织对亚洲人群的分类，将患者分为四组：体重不足（BMI < 18.5 kg/m2）、正常体重（BMI 18.5-22.9 kg/m2）、超重（BMI 23.0-27.4 kg/m2）和肥胖（BMI ≥ 27.5 kg/m2）。分析这四个BMI组的长期生存率差异。结果：低体重组、正常体重组、超重组和肥胖组的5年无瘤生存率分别为44%、61%、68%和73（p = 0.014），5年总生存率分别为51%、68%、80%和72%（p = 0.001）。BMI是一个非常有利的预后因素的总生存期和失败的生存在考克斯回归model.Conclusions：治疗前的体重指数是一个简单的，可靠的独立的预后因素，局部晚期鼻咽癌患者的放化疗治疗。(C)2013爱思唯尔有限公司保留所有权利。
Objective: To investigate the relationship between the pretreatment body mass index (BMI) and the clinical outcomes in patients with locoregionally advanced nasopharyngeal carcinoma treated with combination of chemotherapy and radiotherapy.Methods: From August 2002 to April 2005, 400 patients with stage III or stage IVa nasopharyngeal carcinoma were recruited for a randomised clinical trial of induction chemotherapy combined with radiotherapy or concurrent chemoradiotherapy. The patients were divided into four groups of underweight (BMI < 18.5 kg/m(2)), normal weight (BMI 18.5-22.9 kg/m(2)), overweight (BMI 23.0-27.4 kg/m(2)) or obese (BMI >= 27.5 kg/m(2)) according to the World Health Organization classifications for Asian populations. The differences in the long-term survival, of these four BMI groups were analysed.Results: The 5-year failure-free survival rates for the underweight, normal weight, overweight and obese groups were 44%, 61%, 68% and 73%, respectively (p = 0.014), and the 5-year overall survival rates were 51%, 68%, 80% and 72% (p = 0.001), respectively. BMI was a strongly favoured prognostic factor of overall survival and failure-free survival in a Cox regression model.Conclusions: Pretreatment body mass index was a simple, reliable independent prognostic factor for patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. (C) 2013 Elsevier Ltd. All rights reserved.